Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation

Journal of Immunology

Volumn 185, Issue 8, 2010, Pages 4659-4672

  Cedeno Laurent, Filiberto ^a,b   Barthel, Steven R ^a,b   Opperman, Matthew J ^a   Lee, David M ^b,c   Clark, Rachael A ^a,b   Dimitroff, Charles J ^a,b  

^a Department of Dermatology ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CHIMERIC PROTEIN; CYTOKINE; FC RECEPTOR; GALECTIN 1; GAMMA INTERFERON; HOMODIMER; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; ISOPROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; LIGAND; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CELL DEATH; CONTACT ALLERGY; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; LEUKEMIA CELL; LEUKOCYTE; LEUKOCYTE CULTURE; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; CONTACT DERMATITIS; GENETIC TRANSFECTION; IMMUNOLOGY; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; METABOLISM; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CYTOKINES; DERMATITIS, CONTACT; GALECTIN 1; HUMANS; IMMUNOPRECIPITATION; LEUKOCYTES; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSFECTION;

EID: 78049493865     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000715     Document Type: Article

References (52)

1. Ilarregui, J. M., D. O. Croci, G. A. Bianco, M. A. Toscano, M. Salatino, M. E. Vermeulen, J. R. Geffner, and G. A. Rabinovich. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10:981-991.
2. Garín, M. I., C. C. Chu, D. Golshayan, E. Cernuda-Morollón, R. Wait, and R. I. Lechler. 2007. Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells. Blood 109:2058-2065.
3. Motran, C. C., K. M. Molinder, S. D. Liu, F. Poirier, and M. C. Miceli. 2008. Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur. J. Immunol. 38:3015-3027.
4. Toscano, M. A., G. A. Bianco, J. M. Ilarregui, D. O. Croci, J. Correale, J. D. Hernandez, N. W. Zwirner, F. Poirier, E. M. Riley, L. G. Baum, and G. A. Rabinovich. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8:825-834.
5. Karmakar, S., S. R. Stowell, R. D. Cummings, and R. P. McEver. 2008. Galectin-1 signaling in leukocytes requires expression of complex-type N-glycans. Glycobiology 18:770-778.
6. Van den Brûle, F. A., P. L. Fernandez, C. Buicu, F. T. Liu, P. Jackers, R. Lambotte, and V. Castronovo. 1997. Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev. Dyn. 209:399-405.
7. He, J., and L. G. Baum. 2006. Galectin interactions with extracellular matrix and effects on cellular function. Methods Enzymol. 417:247-256.
8. Blois, S. M., J. M. Ilarregui, M. Tometten, M. Garcia, A. S. Orsal, R. Cordo-Russo, M. A. Toscano, G. A. Bianco, P. Kobelt, B. Handjiski, et al. 2007. A pivotal role for galectin-1 in fetomaternal tolerance. Nat. Med. 13:1450-1457.
9. Perillo, N. L., C. H. Uittenbogaart, J. T. Nguyen, and L. G. Baum. 1997. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J. Exp. Med. 185:1851-1858.
10. Jung, E. J., H. G. Moon, B. I. Cho, C. Y. Jeong, Y. T. Joo, Y. J. Lee, S. C. Hong, S. K. Choi, W. S. Ha, J. W. Kim, et al. 2007. Galectin-1 expression in cancerassociated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int. J. Cancer 120:2331-2338.
11. Perillo, N. L., K. E. Pace, J. J. Seilhamer, and L. G. Baum. 1995. Apoptosis of T cells mediated by galectin-1. Nature 378:736-739.
12. Dias-Baruffi, M., H. Zhu, M. Cho, S. Karmakar, R. P. McEver, and R. D. Cummings. 2003. Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J. Biol. Chem. 278:41282-41293.
13. Stowell, S. R., S. Karmakar, C. M. Arthur, T. Ju, L. C. Rodrigues, T. B. Riul, M. Dias-Baruffi, J. Miner, R. P. McEver, and R. D. Cummings. 2009. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol. Biol. Cell 20:1408-1418.
14. Stowell, S. R., S. Karmakar, C. J. Stowell, M. Dias-Baruffi, R. P. McEver, and R. D. Cummings. 2007. Human galectin-1,-2, and-4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109:219-227.
15. Juszczynski, P., J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104:13134-13139.
16. Perone, M. J., S. Bertera, W. J. Shufesky, S. J. Divito, A. Montecalvo, A. R. Mathers, A. T. Larregina, M. Pang, N. Seth, K. W. Wucherpfennig, et al. 2009. Suppression of autoimmune diabetes by soluble galectin-1. J. Immunol. 182:2641-2653.
17. van der Leij, J., A. van den Berg, T. Blokzijl, G. Harms, H. van Goor, P. Zwiers, R. van Weeghel, S. Poppema, and L. Visser. 2004. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J. Pathol. 204:511-518.
18. Stowell, S. R., Y. Qian, S. Karmakar, N. S. Koyama, M. Dias-Baruffi, H. Leffler, R. P. McEver, and R. D. Cummings. 2008. Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J. Immunol. 180:3091-3102.
19. Baum, L. G., J. J. Seilhamer, M. Pang, W. B. Levine, D. Beynon, and J. A. Berliner. 1995. Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj. J. 12:63-68.
20. Cho, M., and R. D. Cummings. 1995. Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. II. Localization and biosynthesis. J. Biol. Chem. 270:5207-5212.
21. Pace, K. E., H. P. Hahn, and L. G. Baum. 2003. Preparation of recombinant human galectin-1 and use in T-cell death assays. Methods Enzymol. 363:499-518.
22. Nishi, N., A. Abe, J. Iwaki, H. Yoshida, A. Itoh, H. Shoji, S. Kamitori, J. Hirabayashi, and T. Nakamura. 2008. Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1. Glycobiology 18:1065-1073.
23. Tsai, C. M., Y. K. Chiu, T. L. Hsu, I. Y. Lin, S. L. Hsieh, and K. I. Lin. 2008. Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J. Immunol. 181:4570-4579.
24. Barthel, S. R., G. K. Wiese, J. Cho, M. J. Opperman, D. L. Hays, J. Siddiqui, K. J. Pienta, B. Furie, and C. J. Dimitroff. 2009. Alpha 1, 3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc. Natl. Acad. Sci. USA 106:19491-19496.
25. Clark, R. A., B. F. Chong, N. Mirchandani, K. Yamanaka, G. F. Murphy, R. K. Dowgiert, and T. S. Kupper. 2006. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J. Invest. Dermatol. 126:1059-1070.
26. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324.
27. Howard, M. R., A. P. Lodge, J. E. Reed, C. J. McNamee, and D. J. Moss. 2002. High-level expression of recombinant Fc chimeric proteins in suspension cultures of stably transfected J558L cells. Biotechniques 32:1282-1286, 1288.
28. von Gunten, S., D. F. Smith, R. D. Cummings, S. Riedel, S. Miescher, A. Schaub, R. G. Hamilton, and B. S. Bochner. 2009. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J. Allergy Clin. Immunol. 123:1268-1276.e15.
29. Leppänen, A., S. Stowell, O. Blixt, and R. D. Cummings. 2005. Dimeric galectin-1 binds with high affinity to alpha2, 3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J. Biol. Chem. 280:5549-5562.
30. Hirabayashi, J., T. Hashidate, Y. Arata, N. Nishi, T. Nakamura, M. Hirashima, T. Urashima, T. Oka, M. Futai, W. E. Muller, et al. 2002. Oligosaccharide specificity of galectins: A search by frontal affinity chromatography. Biochim. Biophys. Acta 1572:232-254.
31. Levi, G., and V. I. Teichberg. 1981. Isolation and physicochemical characterization of electrolectin, a beta-D-galactoside binding lectin from the electric organ of Electrophorus electricus. J. Biol. Chem. 256:5735-5740.
32. Hirabayashi, J., and K. Kasai. 1991. Effect of amino acid substitution by siteddirected mutagenesis on the carbohydrate recognition and stability of human 14-kDa beta-galactoside-binding lectin. J. Biol. Chem. 266:23648-23653.
33. Pace, K. E., C. Lee, P. L. Stewart, and L. G. Baum. 1999. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 163:3801-3811.
34. Gainers, M. E., L. Descheny, S. R. Barthel, L. Liu, M. A. Wurbel, and C. J. Dimitroff. 2007. Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J. Immunol. 179:8509-8518.
35. Stowell, S. R., M. Cho, C. L. Feasley, C. M. Arthur, X. Song, J. K. Colucci, S. Karmakar, P. Mehta, M. Dias-Baruffi, R. P. McEver, and R. D. Cummings. 2009. Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimer formation. J. Biol. Chem. 284:4989-4999.
36. van der Leij, J., A. van den Berg, G. Harms, H. Eschbach, H. Vos, P. Zwiers, R. van Weeghel, H. Groen, S. Poppema, and L. Visser. 2007. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol. Immunol. 44:506-513.
37. Di Lella, S., L. Ma, J. C. Ricci, G. A. Rabinovich, S. A. Asher, and R. M. Alvarez. 2009. Critical role of the solvent environment in galectin-1 binding to the disaccharide lactose. Biochemistry 48:786-791.
38. Kingsley, C. I., M. Karim, A. R. Bushell, and K. J. Wood. 2002. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4-and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168:1080-1086.
39. Chai, J. G., J. Y. Tsang, R. Lechler, E. Simpson, J. Dyson, and D. Scott. 2002. CD4+CD25+ T cells as immunoregulatory T cells in vitro. Eur. J. Immunol. 32:2365-2375.
40. Kryczek, I., R. Liu, G. Wang, K. Wu, X. Shu, W. Szeliga, L. Vatan, E. Finlayson, E. Huang, D. Simeone, et al. 2009. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 69:3995-4000.
41. Clark, R. A., and T. S. Kupper. 2007. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 109:194-202.
42. Toscano, M. A., A. G. Commodaro, J. M. Ilarregui, G. A. Bianco, A. Liberman, H. M. Serra, J. Hirabayashi, L. V. Rizzo, and G. A. Rabinovich. 2006. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2-and T regulatory-mediated anti-inflammatory responses. J. Immunol. 176:6323-6332.
43. Santucci, L., S. Fiorucci, F. Cammilleri, G. Servillo, B. Federici, and A. Morelli. 2000. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. Hepatology 31:399-406.
44. Baum, L. G., D. P. Blackall, S. Arias-Magallano, D. Nanigian, S. Y. Uh, J. M. Browne, D. Hoffmann, C. E. Emmanouilides, M. C. Territo, and G. C. Baldwin. 2003. Amelioration of graft versus host disease by galectin-1. Clin. Immunol. 109:295-307.
45. Armour, K. L., M. R. Clark, A. G. Hadley, and L. M. Williamson. 1999. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29:2613-2624.
46. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604.
47. Cho, M., and R. D. Cummings. 1995. Galectin-1, a beta-galactoside-binding lectin in Chinese hamster ovary cells. I. Physical and chemical characterization. J. Biol. Chem. 270:5198-5206.
48. López-Lucendo, M. F., D. Solís, S. André, J. Hirabayashi, K. Kasai, H. Kaltner, H. J. Gabius, and A. Romero. 2004. Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by singlesite mutations and their impact on the thermodynamics of ligand binding. J. Mol. Biol. 343:957-970.
49. Adkins, B., Y. Bu, E. Cepero, and R. Perez. 2000. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J. Immunol. 164:2347-2353.
50. Landolfi, N. F. 1991. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J. Immunol. 146:915-919.
51. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
52. Way, J. C., S. Lauder, B. Brunkhorst, S. M. Kong, A. Qi, G. Webster, I. Campbell, S. McKenzie, Y. Lan, B. Marelli, et al. 2005. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel. 18:111-118.